Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Ascendis Pharma A (ASND) over the last 7 years, with Q4 2025 value amounting to $461.0 million.

  • Ascendis Pharma A's Total Non-Current Liabilities rose 1433.0% to $461.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $461.0 million, marking a year-over-year increase of 1433.0%. This contributed to the annual value of $447.5 million for FY2025, which is 1098.62% up from last year.
  • Ascendis Pharma A's Total Non-Current Liabilities amounted to $461.0 million in Q4 2025, which was up 1433.0% from $400.2 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Total Non-Current Liabilities ranged from a high of $798.9 million in Q3 2023 and a low of $108.0 million during Q1 2021
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $393.7 million (2024), whereas its average is $418.7 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 6173936.43% in 2021, then plummeted by 6220.68% in 2023.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Total Non-Current Liabilities stood at $112.1 million in 2021, then soared by 496.4% to $668.4 million in 2022, then tumbled by 62.21% to $252.6 million in 2023, then skyrocketed by 59.63% to $403.2 million in 2024, then rose by 14.33% to $461.0 million in 2025.
  • Its Total Non-Current Liabilities was $461.0 million in Q4 2025, compared to $400.2 million in Q3 2025 and $385.4 million in Q2 2025.